 |
Drug Insight: Gastrointestinal and Hepatic Adverse Effects of Molecular-Targeted Agents in Cancer Therapy CME DisclosuresRelease Date: March 18, 2008; Valid for credit through March 18, 2009 |
| Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | |
| Contents of This CME Activity | |
| To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.
- Drug Insight: Gastrointestinal and Hepatic Adverse Effects of Molecular-Targeted Agents in Cancer Therapy
Yohann Loriot, MD
Gabriel Perlemuter, MD
David Malka, MD, PhD
Frédérique Penault-Lorca, MD
Valérie Boige, MD
Eric Deutsch, MD, PhD
Christophe Massard, MD, MSc
Jean Pierre Armand, MD
Jean-Charles Soria, MD, PhD
Go to Test Questions |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe the clinical presentation of diarrhea caused by molecular targeted therapy
- Specify a recommended treatment for diarrhea caused by molecular targeted therapy
- Describe hepatitis associated with molecular targeted
therapy
- Identify the pathophysiology and clinical management of elevated pancreatic enzymes associated with molecular targeted therapy
Authors and Disclosures Yohann Loriot, MD
Disclosure: Yohann Loriot, MD, has disclosed no relevant financial relationships. Gabriel Perlemuter,
MD
Disclosure: Gabriel Perlemuter, MD, has disclosed no relevant financial relationships. David Malka, MD, PhD
Disclosure: David Malka, MD, PhD, has declared that he is on the speakers bureau for Merck, Pfizer, Roche, sanofi-aventis and Serano, and receives grant or research support from Merck, Roche, sanofi-aventis and Serano. Frédérique Penault-Lorca,
MD
Disclosure: Frédérique Penault-Lorca, MD, has disclosed no relevant financial relationships. Valérie Boige, MD
Disclosure: Valérie Boige, MD, has disclosed no relevant financial relationships. Eric Deutsch, MD, PhD
Disclosure: Eric Deutsch, MD, PhD, has disclosed no relevant financial relationships.
Christophe Massard, MD, MSc
Disclosure: Christophe Massard, MD, MSc, has disclosed no relevant financial relationships. Jean Pierre Armand, MD
Disclosure: Jean Pierre Armand, MD, has disclosed no relevant financial relationships. Jean-Charles Soria, MD, PhD
Disclosure: Jean-Charles Soria, MD, PhD, has declared a
consultant relationship with Roche, sanofi-aventis, and Wyeth. Dr. Soria has also declared that he receives grant or research support from Eli Lilly. Charles P. Vega, MD
Disclosure: Charles P. Vega, MD, has disclosed that he has served as an advisor or consultant to Novartis, Inc. Lisa Hutchinson
Disclosure: Lisa Hutchinson has disclosed no relevant
financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
